NCT06809140 2026-02-23Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder CancerHoosier Cancer Research NetworkPhase 2 Recruiting47 enrolled